Citace podle APA

Latimer, N. R., Abrams, K. R., Amonkar, M. M., Stapelkamp, C., & Swann, R. S. (2015). Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine. Oncologist.

Styl Chicago

Latimer, Nicholas R., Keith R. Abrams, Mayur M. Amonkar, Ceilidh Stapelkamp, a R. Suzanne Swann. "Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine." Oncologist 2015.

Citace podle MLA

Latimer, Nicholas R., et al. "Adjusting for the Confounding Effects of Treatment Switching—The BREAK-3 Trial: Dabrafenib Versus Dacarbazine." Oncologist 2015.

Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..